spacer
The Healthcare Sales & Marketing Network celebrates 24 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  fludarabine 

 HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2016
AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2015
Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Oct 2013
Lorus Therapeutics Appoints New Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Oct 2013
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2013
Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
Biopharmaceuticals Litigation
 HSMN NewsFeed - 25 Mar 2013
Arzerra Receives Approval in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2012
Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Aug 2012
Genmab Enters Worldwide Agreement With Janssen for Daratumumab
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 Apr 2012
New Drug Application for Arzerra Submitted in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Nov 2010
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Mar 2010
Declaratory Relief Complaint for Patent Infringement Under Patent Based on Manufacture, Marketing and Sale of Arzerra
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 22 Jan 2010
Arzerra(TM) (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 May 2009
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 5 Feb 2009
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Dec 2008
Antisoma receives FDA approval for oral fludarabine, plans commercialisation deal to bring drug to US patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jul 2008
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2008
Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2008
Spectrum Pharmaceuticals Announces Sale of Injectable Generic Drugs to Sagent Pharmaceuticals, Inc.
Biopharmaceuticals Generics
 HSMN NewsFeed - 17 Mar 2008
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2008
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2007
Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2007
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jul 2007
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 17 May 2007
Cell Therapeutics, Inc. Receives FDA Special Protocol Assessment (SPA) Comments on the Design of Phase III Trial of Pixantrone in Relapsed Indolent NHL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 May 2007
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2007
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Apr 2007
Genta Appeals FDA Decision on Genasense(R) in CLL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2007
Genta Cites Publication of Study Showing Improved Outcomes in CLL Patients Treated With Genasense(R) Plus Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2007
Genta Announces the Company Will Appeal FDA Action on New Drug Application of Genasense(R) in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2007
Nektar Appoints Howard W. Robin President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Dec 2006
'Impressive' Complete Remission and 'Durable' Survival Data in Relapsed Indolent NHL Patients Identifies New Potential Registration Trial for Pixantrone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
Genta Provides Update on Analysis of Phase 3 Trial of Genasense(R) in Older Patients with Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane(R) and Temodar(R) as First-Line Therapy for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2006
Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients with Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2006
Genasense(R) Receives Orphan Drug Designation in Australia for Patients With Advanced Melanoma
Biopharmacetuicals Oncology Regulatory
 HSMN NewsFeed - 6 Oct 2006
Genta Receives Special Protocol Assessment from FDA for Randomized Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2006
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Aug 2006
Genta Revises Notice of Special Protocol Assessment for Confirmatory Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jul 2006
Genzyme Launches New Diagnostic Test for Common Blood Cancer
Diagnositcs Oncology
 HSMN NewsFeed - 27 Jul 2006
Genta Announces FDA's Oncology Drug Advisory Committee Will Review Genasense(R) as Treatment for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Jul 2006
Genta Receives Special Protocol Assessment from FDA for Confirmatory Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jun 2006
Genzyme and Berlex Oncology Announce Interim Results of Campath in First-Line Study of Chronic Lymphocytic Leukemia at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2006
Vion Pharmaceuticals Provides Update for Clinical and Preclinical Programs
Biopharmaceuticals
 HSMN NewsFeed - 23 Mar 2006
Genta and Emisphere Technologies Enter into Exclusive Worldwide Licensing Agreement for Development of an Oral Gallium Compound
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Mar 2006
Randomized Trial Shows Ganite(R) Effective When Compared with a Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia
Biopharmaceuticals
 HSMN NewsFeed - 1 Mar 2006
Genasense(R) New Drug Application Accepted for Review by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Feb 2006
Analysis of Genasense(R) Trial Confirms Major Efficacy Variables in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Feb 2006
Genasense(R) Marketing Authorization Application in Melanoma Accepted for Review by European Regulatory Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jan 2006
Subcutaneous Genasense(R) Trial Initiated in Patients with Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jan 2006
Genta Appoints Dr. Per Lindell as Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2006
Genta Appoints Seasoned Pharma Executive, Lloyd Sanders, as Vice-President for Sales and Marketing
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jan 2006
BioCryst Receives FDA Fast Track Designation for Peramivir
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 63

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 63 additional stories matching:
fludarabine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.